STALICLA
REPO4EU consortium seeks to address the urgent need for new cost-effective therapies, as well as to improve existing treatments through international cooperation, pooling research and innovation expertise. A total of EUR 22 million grant has been awarded to REPO4EU by EU (HORIZON-HLTH-DISEASE-2021-04-02) within the Key Strategic Orientation KSO-D ‘Creating a more resilient, inclusive and democratic European society’ of Horizon Europe’s Strategic Plan 2021-2024. REPO4EU is one of the only two projects retained among 13 full consortium applications. STALICLA DDS was granted a EUR 1.7 million budget over 6 years to act as leader for in silico drug repositioning work tasks. STALICLA DDS will bring its technology and know-how to analyze biosample and clinical data from hundreds of patients with neurodevelopmental disorders (NDDs).
Lynn DURHAM, STALICLA’s CEO stated that “STALICLA is thrilled to be leading the REPO4EU in silico drug repositioning work task project. This achievement is a strong acknowledgement of STALICLA’s technology and expertise in accelerating precision medicine discovery for patients with complex diseases.”
It takes on average 15 years for promising drug candidates to reach the market. Repositioning investigational medicinal products beyond their original pursued indication is an efficient strategy to reduce timelines, costs and attrition in drug development. STALICLA will contribute to REPO4EU its unique know-how of in silico systems biology and artificial intelligence applications for patient stratification and treatment identification.
For more information see:
REPO4EU consortium web https://repo4.eu/ and twitter https://twitter.com/REPO4EU
The funding call https://cordis.europa.eu/programme/id/HORIZON_HORIZON-HLTH-2021-DISEASE-04-02 and info on the resolution of the call https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2021-disease-04-02
About STALICLA
STALICLA is a clinical stage biotech company advancing the first clinically validated precision medicine platform for patients with Neurodevelopmental Disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).
STALICLA has already identified and validated clinically and biologically several subgroups of patients with ASD and corresponding treatment candidates.
STP1, STALICLA’s first lead treatment, aims to serve a first biological subgroup of patients with ASD- ASD-Phenotype 1.
STP1 has successfully completed clinical Phase 1b in early 2022, showing good safety/tolerability, positive target engagement, and superiority in cognition endpoints in treatment versus placebo groups. In 2023, STP1 will enter Phase 2; STP2, a phase 2 ready compound tailored for the treatment of ASD-Phenotype 2 patients will also be entering Phase 2. For more information, please visit: https://stalicla.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005408/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Global Survey Reveals Oracle Database Customers are Evolving their Database Strategies Citing High Costs, Support Challenges and Need for Advanced AI/ML Capabilities4.11.2025 21:43:00 CET | Press release
Third-party support provides Oracle Database customers with significant cost savings and premium support, allowing organizations to focus their resources toward AI/ML and LLM initiatives Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the findings of the 2025 Database Strategies and Support Survey – The Diversification and Decentralization Revolution, a global study conducted by Unisphere Research of more than 200 Oracle Database managers and practitioners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104640087/en/ New Global Survey Reveals Oracle Database Customers are Evolving their Database Strategies Citing High Costs, Support Challenges and Need for Advanced AI/ML Capabilities Oracle Database Customers Face Suppor
TRU Simulation receives Japanese Civil Aviation Bureau qualification for the SUBARU Bell 412EPX Flight Training Device, delivering next-level realism to rotorcraft training operators in Japan4.11.2025 21:30:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Bell Textron Inc., today announced the SUBARU Bell 412EPX Flight Training Device (FTD) has received Level 5 qualification from the Japanese Civil Aviation Bureau (JCAB), marking a significant milestone in advancing rotorcraft training capabilities in Japan. Developed in collaboration with Bell, the FTD supports SUBARU’s mission in civil aviation by enabling pilots to train for a wide range of operations—from routine transport to complex search and rescue (SAR) missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104983178/en/ TRU Simulation receives Japanese Civil Aviation Bureau qualification for the SUBARU Bell 412EPX Flight Training Device, delivering next-level realism to rotorcraft training operators in Japan “SUBARU pilots flying some of Japan’s most critical missions now have access to immersive, high-fidelity training that b
PennAero and Tinicum Announce Acquisition of TriMas Aerospace4.11.2025 20:17:00 CET | Press release
Tinicum, L.P. (“Tinicum”) today announced that one of its affiliates has signed an agreement to acquire the aerospace assets of TriMas Corporation (“TriMas Aerospace”), through which TriMas Aerospace will be merged with PennAero, a Tinicum portfolio company (“the Transaction”). Funds managed by Blackstone will be a minority investor in the Transaction. This investment reinforces PennAero’s strategy of partnering with its customers to provide best-in-class engineering, manufacturing, customer service and support. TriMas Aerospace is a leading provider of highly engineered fasteners and precision-machined components for mission-critical applications across the global commercial aerospace and defense industries. Backed by a portfolio of trusted brands, including Monogram Aerospace Fasteners™, Allfast Fastening Systems®, Mac Fasteners™, TFI Aerospace, TriMas Aerospace Germany, Martinic Engineering™, RSA Engineered Products™ and Weldmac Manufacturing Company, TriMas Aerospace delivers innov
BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia4.11.2025 19:50:00 CET | Press release
In a major step toward advancing pharmaceutical local content and national drug security, BOSTON ONCOLOGY ARABIA and the Local Content & Government Procurement Authority (LCGPA) have signed an agreement to localize the manufacture of two biosimilar medicines within the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104239476/en/ Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncology Arabia at the Global Health Exhibition 2025 in Riyadh, following the signing of an agreement to localize the manufacturing of advanced biologic medicines. The partnership builds on Boston Oncology Arabia’s fully integrated Saudi operations and its leadership in transferring global biopharma expertise to strengthen national drug security, expand local value creation, and deliver sustainable access to high-quality biologic therapies in line with Vision 2030. The signing ceremony took place
ClickHouse Acquires LibreChat to Democratize AI-Driven Analytics Through the Open-Source Agentic Data Stack4.11.2025 18:00:00 CET | Press release
ClickHouse, Inc., the company behind the world’s fastest and most popular real-time analytics database, today announced the acquisition of LibreChat, a leading open-source AI chat platform that provides a unified interface for interacting with large language models (LLMs). The acquisition brings LibreChat founder Danny Avila and his team to ClickHouse. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104505230/en/ ClickHouse acquires LibreChat: Introducing the open-source Agentic Data Stack Together, ClickHouse and LibreChat form the foundation of the open-source Agentic Data Stack, empowering teams to deploy AI agents that analyze and act on large datasets through natural language. This shift to agentic analytics is already transforming how organizations such as Shopify, Daimler Truck, Fetch, and cBioPortal leverage their data, demonstrating the immediate value in real-world applications. At Shopify, LibreChat has become c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom